Inclusion Criteria:

• Diagnosis of discoid/subacute cutaneous lupus erythematosus (DLE/SCLE) for at least 3 months prior to screening visit.
• Meets both clinical and histopathological diagnostic cutaneous lupus erythematosus (CLE) criteria per protocol.
• Currently receiving treatment for DLE/SCLE with a stable regimen of at least one of the following medications: oral corticosteroid, and/or antimalarial, and/or immunosuppressant.
• Participant could be with or without concurrent systemic lupus erythematosus (SLE).
• If participant receives nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics treatment then the participant must be on a stable dose 2 weeks prior to screening.

Exclusion Criteria:

• Women who are pregnant, lactating, breastfeeding or planning pregnancy during the study period.
• Any of the following specific CLE subtypes in isolation: acute cutaneous lupus erythematosus (ACLE), lupus tumidus, lupus (profundus) panniculitis, chilblains.
• Drug-induced CLE and/or drug-induced systemic lupus erythematosus (SLE).
• Antiphospholipid antibody syndrome, serious thrombotic event or unexplained pregnancy loss within 1 year before the screening visit.
• History of 3 or more unexplained consecutive pregnancy losses.
• Active severe or unstable neuropsychiatric SLE.
• Other autoimmune diseases or non-SLE driven inflammatory joint or skin disease or overlap syndromes as primary disease that in the opinion of the investigator will significantly impact the assessment of CLE/SLE disease manifestations and activity.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/21/23. Questions regarding updates should be directed to the study team contact.